Bicycle Therapeutics (BCYC) Operating Margin (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Operating Margin came in at 8673.93% in Q2 2026, down 570810.0% YoY from N/an in Q2 2025, and down 17.49% on a QoQ basis from 7382.41% in Q1 2026.
Powered by 
Analysis
Bicycle Therapeutics (BCYC) Operating Margin (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Operating Margin data on file, last reported at 8673.93% in Q2 2026.
- Quarterly Operating Margin fell 570810.0% year-over-year to 8673.93% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 343.6% (up 115173.0% YoY) and the FY2025 annual result came in at 340.38%, up 25458.0% from the prior year.
- Operating Margin eased to 8673.93% in Q2 2026, from 7382.41% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 51.52% in Q4 2025 to a low of 8673.93% in Q2 2026.
- A 5-year average of 1719.18% and a median of 781.61% in 2023 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2025 — Operating Margin jumped 182723 bps — and 2026, when it plunged 667875 bps.
- Tracing BCYC's Operating Margin over 5 years: stood at 383.46% in 2022, then slumped by 165 bps to 1017.35% in 2023, then plunged by 79 bps to 1824.78% in 2024, then surged by 97 bps to 51.52% in 2025, then slumped by 16735 bps to 8673.93% in 2026.
- The last three Operating Margin figures came in at 8673.93% (Q2 2026), 7382.41% (Q1 2026), and 51.52% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Bicycle Therapeutics | 299.81 Mn | 299.81 Mn | - | -8,673.93% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -8,673.93% |
| Mar 31, 2026 | -7,382.41% |
| Dec 31, 2025 | -51.52% |
| Sep 30, 2025 | -558.64% |
| Jun 30, 2025 | -2,965.82% |
| Mar 31, 2025 | -703.66% |
| Dec 31, 2024 | -1,824.78% |
| Sep 30, 2024 | -2,385.87% |
| Jun 30, 2024 | -498.31% |
| Mar 31, 2024 | -162.40% |
| Dec 31, 2023 | -1,017.35% |
| Sep 30, 2023 | -949.12% |
| Jun 30, 2023 | -378.27% |
| Mar 31, 2023 | -853.82% |
| Dec 31, 2022 | -383.46% |
| Sep 30, 2022 | -978.91% |
| Jun 30, 2022 | -325.00% |
| Mar 31, 2022 | -709.40% |
| Dec 31, 2021 | -1,126.50% |
| Sep 30, 2021 | -329.89% |